Sentrian expected to transform RPM from a basic report-and-flag model to an evolving analytical response solution that detects health deterioration earlier and with higher accuracy
MOUNTAIN VIEW, Calif., Oct. 6, 2015 /PRNewswire/ — Based on its recent analysis of the remote patient monitoring (RPM) market, Frost & Sullivan recognizes Sentrian with the 2015 North American Frost & Sullivan Award for Technology Innovation. Sentrian aims to make a success of RPM with its remote patient intelligence (Sentrian RPI) solution, a data-driven system that can develop the complex algorithms necessary to extract additional value from RPM. The company hopes to transform data sets to actionable intelligence that will help detect health deterioration early and accurately, and increase the efficiency of remote care managers.
Sentrian recognized that patients with multiple chronic diseases that may need several hospital admissions would benefit most from its analytics-based solution. As false positives have been a significant barrier to RPM’s adoption, Sentrian has used business intelligence techniques to evaluate numerous parameters and parameter combinations for both short- and long-term trends. These data are then compared with a patient’s personal baseline so that a response may be initiated only when it is truly needed.
The Sentrian RPI is the first system to allow clinicians to rapidly build new remote disease deterioration models and uses machine learning to continuously enhance the models. As the platform is device- and gateway-agnostic, it can select the appropriate biosensors and less intrusive wearable devices to lower costs and improve compliance. The actual array is determined following a risk assessment for each patient.
Significantly, owing to its device-agnostic approach and machine-learning model evaluation engine, Sentrian can be deployed as a stand-alone solution or become an infrastructure component of larger population health systems offered by other market participants as well. Its solution is part of Anthem programs, including one aimed at reducing hospitalization in patients with chronic obstructive pulmonary disease (COPD). Its disease deterioration modeling system, which includes rich input from clinicians in the form of natural language, is combined with historical data and machine learning to continuously improve the performance of the models. This solution is anticipated to break RPM’s adoption barriers and make RPM scalable for the first time.
Frost & Sullivan notes that although Sentrian is still developing its solution, it has devised ways to apply it in measurable studies that will demonstrate product impact. For instance, the Sentrian RPI platform already has clinical study evidence that demonstrates it can detect health deterioration predictive of hospitalization at nearly twice the accuracy of common RPM systems.
“The essence of Sentrian’s solution is to enable scalability and avoid the deluge of unfiltered data that makes many potential RPM customers wary of large-scale solutions,” said Frost & Sullivan Industry Principal Analyst Victor Camlek.”Using advanced relationship-driven algorithms rather than merely flagging single-indicator readings, the company is expecting to overcome issues regarding scalability and, ultimately, boost the popularity of RPM.
“The next step for Sentrian’s big data predictive analytics platform will be the personalization of both clinical and non-clinical interventions. Sentrian will track care team interventions as well as results to determine the interventions that are most likely to prevent a hospital admission or other negative health events for each patient. Although there are many companies that provide RPM, Sentrian, with its data filters, analytics and predictive models, is further along the developmental pipeline. The first version of its solution has already been developed, is Food and Drug Administration 510K exempt, available for broad use, and is being deployed by large healthcare organizations.”
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry, and the positive impact on brand perception.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
Sentrian™, the Remote Patient Intelligence™ company aspiring to eliminate all preventable hospitalization, was founded to help “at-risk” organizations improve their shared savings performance by reducing hospitalization in their highest-risk patients. The Sentrian end-to-end remote patient intelligence solution leverages the revolution in wearable, multi-modal biosensors and machine learning to detect health deterioration in high-risk patients earlier and with higher accuracy so lower-cost interventions can be utilized before the patient becomes acute and requires hospitalization. The Sentrian solution is commercially available, FDA 501K Exempt, and designed to seamlessly integrate with existing healthcare information systems and clinical workflows, facilitating adoption. Sentrian is the sole winner of the American Telemedicine Association’s 2015 President’s Award for Innovation in Remote Health Care. Find us atwww.sentrian.com, on Twitter and LinkedIn.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
P: 210. 247.3870
E: [email protected]
Sentrian™, the first Remote Patient Intelligence™ company, aspires to eliminate all preventable hospitalization by leveraging the revolution in remote biosensors and machine learning to detect patient deterioration early, before it becomes acute. Sentrian’s value proposition to healthcare organizations is to provide a cloud-based remote patient monitoring and analytics platform intended to dramatically reduce preventable hospital admissions, increase the efficiency and effectiveness of care teams and improve quality metrics such as HEDIS and Star ratings. The Sentrian platform is designed to seamlessly integrate with existing healthcare information systems and clinical workflows, facilitating adoption. Find us at www.sentrian.com, on Twitter and LinkedIn.